Thu, Nov 14, 2024
The fine was imposed due to an error in the date of the invoice and also in the name of the reference standard versus import license.
More >
Thu, Sep 26, 2024
The drug regulatory body of Mexico has imposed a penalty of MXN 6,51,420 (Rs 28 Lakh) on the company for deviation from prescribed guidelines for filing intimation of import of a reference standard for one of the active pharmaceutical ingredient
Mon, Aug 12, 2024
Earlier, the USFDA had issued a Form 483 with two observations to the two units following inspection which was conducted from May 8 to May 17, 2024.
Fri, Jul 29, 2022
The pharma major reported poor performance on the margins front as well as weak US and Europe sales during the June-end quarter of the financial year 2022-23 (Q1FY23), brokerages believe.
Fri, May 20, 2022
Shares of Dr Reddy's surged eight per cent amid a spurt in volume to Rs 4247 a share on Friday's intraday trade after the company came out with its earnings for the quarter ended March 31, 2022
Thu, May 19, 2022
Dr Reddy's Laboratories Limited reported a 76 per cent declne in its net profit at Rs 88 cr for the quarter ended 31 December. The Profit After Tax (PAT) reported by the company in the corresponding quarter in the year-ago period stood at Rs 362.4 cr
Fri, Mar 25, 2022
Divi’s Laboratories Ltd has risen nearly 30 per cent in the last one year compared to 20 per cent upside seen in the Nifty50 in the same period, and the technical charts suggest that momentum is likely to continue
Wed, Mar 23, 2022
Here's what Santosh Meena, Head of Research, Swastika Investmart Ltd, recommends investors should do with these stocks when the market resumes trading today.
Fri, Mar 04, 2022
Similarly, total 26 stocks from the Nifty500 index such as Ashok Leyland, Apollo Tyres, Ramco Cement, Dalmia Bharat, JK Cements, Kansai Nerolac and SBI Cards and Payment Services among others hit their respective 52-week lows
Thu, Mar 03, 2022
Stocks that were in focus include Maruti Suzuki that closed with losses of over 6 per cent, HDFC Ltd fell nearly 4 per cent and Dr Reddy’s Laboratories was down more than 5 per cent on Wednesday
Fri, Jan 28, 2022
Both top line and bottom line of the company registered positive year-on-year growth, while margins slipped marginally during the quarter.
Wed, Jan 26, 2022
Pharma major Dr Reddy’s Laboratories is likely to report a robust October-December quarter earnings for the financial year 2021-22 on Friday.
Thu, Dec 23, 2021
Organisation of Pharmaceutical Producers of India (OPPI) Director-General K G Ananthakrishnan told PTI that it is crucial for the industry to further build momentum towards the gains secured over the course of the pandemic which will help it carve a niche in the global pharma value chain.
Thu, Dec 09, 2021
Homegrown pharma major Dr Reddy's Laboratories on Thursday said it has launched Valsartan tablets, used for treatment of high blood pressure and heart failure, in the US market.
Wed, Oct 27, 2021
In conversation with Anil Singhvi, Managing Editor at Zee Business, Sanjiv Bhasin, Director-IIFL Securities Ltd picked two stocks that is Dr Reddy's Laboratories Ltd and Dalmia Bharat Ltd for profit booking.
Sat, Sep 04, 2021
Dr Reddy's Laboratories on Saturday said it has inked a pact with US-based Citius Pharmaceuticals to sell its rights to an anti-cancer agent.
Wed, Jul 28, 2021
Dr Reddy’s Laboratories shares continued to decline for the second straight session, it fell around 14 per cent to Rs 4667 a share, day’s low level from Rs 5409 apiece Monday’s close. The company on Tuesday reported lower-than-expected earnings in the first quarter of the financial year 2021-22.
After reporting lower-than-expected first-quarter results, the brokerages are divided on Dr Reddy’s Laboratories prospects, However, the majority of them are maintaining a Neutral or an Underperform ratings on this stock.
Tue, Jul 27, 2021
The pharmaceutical major Dr Reddy’s Laboratories on Tuesday reported a 1 per cent decline in the consolidated net profit to Rs 571 crore in the first quarter of the financial year 2021-2022. The company had posted Rs 579 crore in the same period a year ago (Q1FY21).
Sun, Jul 25, 2021
Stocks to Buy on Monday – Dr Reddy’s Laboratories - Market Analyst Sandeep Jain recommends a stock from the Futures & Options (F&O) space and this is a pharma stock. He recommended Dr Reddy’s Laboratories as his intraday stock for Monday with the target price between 5470 and 5490 while the stop loss at Rs 5390
Thu, Jun 17, 2021
Dr Reddy's Laboratories has informed that being a limited pilot phase presently, registration on CoWIN is not open yet to members of the public.
Sun, May 23, 2021
Amid crisis due to Covid-19 pandemic, a BIG RAY OF HOPE has emerged in terms of treatment of the disease.
Fri, May 14, 2021
Pharma major Dr Reddy’s Laboratories on Friday released its financial year for the quarter ended 31 March 2021, below street’s estimates. The profits declined with a marginal increase in revenues. The company in its filing to exchanges said that the year-on-year (YoY) decline was primarily on account of higher volumes last year due to the pandemic-related stocking up and price erosion.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
